Zorginstituut Nederland

> Return address PO Box 320, 1110 AH Diemen

To the Minister of Health, Welfare and Sport
PO Box 20350
2500 EJ THE HAGUE

2023024746

National Health Care Institute
Care
Medicinal Products

Willem Dudokhof 1
1112 ZA Diemen
PO Box 320
1110 AH Diemen
www.zorginstituutnederland.nl
info@zinl.nl

T +31 (0)20 797 85 55

Contact
Ms N. Stam
warcg@zinl.nl

Our reference
2023024746

Date 31 July 2023
Re: Advisory report on the extension of the conditional inclusion procedure for ataluren (Translarna®)

Dear Mr Kuipers,

On 1 March 2023, you received the Progress report on the conditional inclusion (CI) of orphan drugs, conditionals and exceptionals for the reporting year 2022. In this report, we informed you about the progress of the ongoing CI procedures. We also recommended the continuation of all ongoing CI procedures. It has since become known that the CI procedure for ataluren (Translarna®) has been delayed. This letter is to advise you, based on new developments, to extend this conditional inclusion procedure. This letter is therefore an addendum to the advisory report in the progress reporting mentioned above.

Course of the procedure
Ataluren is conditionally admitted to the basic health care package from 1 November 2021 until 1 February 2024. The medicinal product is registered for the treatment of Duchenne's muscular dystrophy due to a nonsense mutation in the dystrophin gene (nmDMD), in ambulatory patients aged two years and older. So far, fifteen Dutch patients have been given access to ataluren through conditional inclusion. The period of inclusion of the main study has been stopped and the double-blind phase of the study has already been completed.

The end date of the CI procedure had been based on the expectation that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) would deliver an advisory report on the re-evaluation of the European marketing authorization between 30 March and 30 July 2023. Ataluren is currently conditionally permitted on the European market. It has since become known that the CHMP advice has been delayed and is not expected until September 2023. According to the CI procedure, the marketing authorisation holder should submit a reimbursement dossier to the National Health Care Institute as soon as possible after the CHMP advice has been issued. The National Health Care Institute will then issue an advice within 6 months on whether ataluren complies with established medical science and medical practice. Due to the delay in the CHMP advice, there is not enough time available (<6 months) to assess whether ataluren meets the established medical science and medical practice.

Change in PE Exemption Criteria
Recently, the National Health Care Institute decided to modify the criteria for the exemption for the pharmaco-economic (PE) analysis. The National Health Care Institute is now conducting a PE assessment of extramural drugs if during 1 of the first 3 years after market introduction:

- the total costs (macro costs) are € 10 million or more per year; or
- the total costs (macro costs) are between €1 million and €10 million per year with costs per patient per year of €50,000 or more.

This means that in addition to a pharmacotherapeutic dossier and a budget impact analysis, marketing authorisation holders of these medicinal products should also provide a PE evaluation as part of the reimbursement dossier. By changing the above criteria, a PE evaluation should now also be provided for ataluren as part of the reimbursement dossier. There is currently insufficient time available for the marketing authorisation holder to perform a PE evaluation and also to allow sufficient time for the National Health Care Institute to perform the package assessment before the end of the CI procedure (1 February 2024).

Consequences
It is not desirable for the CI procedure for ataluren to end before an advice has been issued by the National Health Care Institute on its inclusion in the health insurance package. This would mean that the reimbursement of ataluren on the basis of the CI would cease and therefore patients would not have access to the product (temporarily).

Advice from the National Health Care Institute
Based on the above considerations, the National Health Care Institute recommends that as of 1 October 2023 the end date of the CI procedure for ataluren be changed from 1 February 2024 to 1 October 2024. This is therefore an extension of 8 months. The marketing authorisation holder should submit a reimbursement dossier to the National Health Care Institute, consisting of a pharmacotherapeutic dossier, a budget impact analysis and a PE evaluation, no later than 6 months after the CHMP advice. The National Health Care Institute will then have sufficient time to issue a package advice. Even with the proposed extension, the CI procedure remains in category 1 (CI duration <7 years) and no intermediate go/no-go moments are required.

Yours sincerely,

Sjaak Wijma
Chairperson of the Executive Board